Delayed and incomplete myelination in a transgenic mouse mutant with abnormal oligodendrocytes

Autor: J M, Orian, A, Slavin, M M, Ayers, C C, Bernard

Publikováno v: Journal of neuroscience research. 50(5)

In search of animal models suitable for investigating myelin repair, we have analysed myelinogenesis in a transgenic mouse mutant with delayed myelination, but with a normal life-span. The 2-50 mutant which carries a c-myc gene under the regulation o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::00e44f1ff15afd672b91e49ec6f33667
https://pubmed.ncbi.nlm.nih.gov/9418968

The Effects of Ethylene Dimethane Suiphonate (EDS) on Rat Leydig Cells: Evidence to Support a Connective Tissue Origin of Leydig Cells1

Autor: Peter O'Leary, D. M. De Kretser, A. E. Jackson, M M Ayers

Publikováno v: Biology of Reproduction. 35:425-437

Ethylene dimetbane sulpbonate (DS) administered to adult male rats in a single dose of 75 mg/kg body weight results in a rapid destruction of Leydig cells which, in turn, is associated with a marked decline in levels of serum testosterone. For 24-72

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b54d5dca0c10ad34cfb5e5b194591e80
https://doi.org/10.1095/biolreprod35.2.425

Structural Aspects of Cigarette Smoke-Induced Pulmonary Disease

Autor: M. M. Ayers, D. F. Rogers, P. A. Shields, P. K. Jefferey

Publikováno v: Smoking and the Lung ISBN: 9781461294689

Smoking is the most important cause of preventable early death and loss of working time in the United Kingdom. Two out of five heavy smokers die before they are 65 - double the proportion of non-smokers. The most serious risk of smoking is lung cance

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::124ae163fa231c8f4723dbbace8e1b71
https://doi.org/10.1007/978-1-4613-2409-6_1

Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC.

Autor: Mok TSK; State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, China. Electronic address: tony@clo.cuhk.edu.hk., Lopes G; Sylvester Comprehensive Cancer Center at the University of Miami, Miami, FL, USA., Cho BC; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea., Kowalski DM; Maria Sklodowska-Curie National Research Institute of Oncology, Department of Lung Cancer and Thoracic Tumours, Warsaw, Poland., Kasahara K; Kanazawa University Hospital, Kanazawa, Japan., Wu YL; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China., de Castro G Jr; Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, Brazil., Turna HZ; Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey., Cristescu R; Merck & Co., Inc., Rahway, NJ, USA., Aurora-Garg D; Merck & Co., Inc., Rahway, NJ, USA., Loboda A; Merck & Co., Inc., Rahway, NJ, USA., Lunceford J; Merck & Co., Inc., Rahway, NJ, USA., Kobie J; Merck & Co., Inc., Rahway, NJ, USA., Ayers M; Merck & Co., Inc., Rahway, NJ, USA., Pietanza MC; Merck & Co., Inc., Rahway, NJ, USA., Piperdi B; Merck & Co., Inc., Rahway, NJ, USA., Herbst RS; Yale University School of Medicine, Yale Cancer Center, New Haven, CT, USA.

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2023 Apr; Vol. 34 (4), pp. 377-388. Date of Electronic Publication: 2023 Jan 25.

Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199).

Autor: Patel VM; Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Balakrishnan K; Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Douglas M; Infinity Pharmaceuticals Inc., Cambridge, MA, USA., Tibbitts T; Infinity Pharmaceuticals Inc., Cambridge, MA, USA., Xu EY; Infinity Pharmaceuticals Inc., Cambridge, MA, USA., Kutok JL; Infinity Pharmaceuticals Inc., Cambridge, MA, USA., Ayers M; Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sarkar A; Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Guerrieri R; Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wierda WG; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA., O'Brien S; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jain N; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Stern HM; Infinity Pharmaceuticals Inc., Cambridge, MA, USA., Gandhi V; Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Publikováno v: Leukemia [Leukemia] 2017 Sep; Vol. 31 (9), pp. 1872-1881. Date of Electronic Publication: 2016 Dec 26.